

Paolo Golino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4114893/publications.pdf>

Version: 2024-02-01

154
papers

5,808
citations

81900
39
h-index

85541
71
g-index

154
all docs

154
docs citations

154
times ranked

6610
citing authors

#	ARTICLE	IF	CITATIONS
1	Divergent Effects of Serotonin on Coronary-Artery Dimensions and Blood Flow in Patients with Coronary Atherosclerosis and Control Patients. <i>New England Journal of Medicine</i> , 1991, 324, 641-648.	27.0	677
2	Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1438-1444.	2.8	493
3	Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. <i>Current Atherosclerosis Reports</i> , 2014, 16, 435.	4.8	413
4	Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries. <i>Journal of the American College of Cardiology</i> , 1989, 13, 755-763.	2.8	320
5	Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. <i>Nature Medicine</i> , 1996, 2, 35-40.	30.7	171
6	Local Effect of Serotonin Released during Coronary Angioplasty. <i>New England Journal of Medicine</i> , 1994, 330, 523-528.	27.0	131
7	C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. <i>Cardiovascular Research</i> , 2005, 68, 47-55.	3.8	126
8	Oleuropein prevents oxidative myocardial injury induced by ischemia and reperfusion. <i>Journal of Nutritional Biochemistry</i> , 2004, 15, 461-466.	4.2	123
9	Patients With Acute Coronary Syndrome Show Oligoclonal T-Cell Recruitment Within Unstable Plaque. <i>Circulation</i> , 2006, 113, 640-646.	1.6	116
10	Antithrombotic Effects of Recombinant Human, Active Site-Blocked Factor VIIa in a Rabbit Model of Recurrent Arterial Thrombosis. <i>Circulation Research</i> , 1998, 82, 39-46.	4.5	82
11	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	2.2	78
12	Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?. <i>Internal and Emergency Medicine</i> , 2009, 4, 25-34.	2.0	75
13	Direct coronary stenting: Effect on coronary blood flow, immediate and late clinical results. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 464-473.	1.7	66
14	Splicing of platelet resident pre-mRNAs upon activation by physiological stimuli results in functionally relevant proteome modifications. <i>Scientific Reports</i> , 2018, 8, 498.	3.3	65
15	Platelet Biology and Receptor Pathways. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 299-309.	2.4	64
16	Tissue Factor Binding of Activated Factor VII Triggers Smooth Muscle Cell Proliferation via Extracellular Signal-Regulated Kinase Activation. <i>Circulation</i> , 2004, 109, 2911-2916.	1.6	63
17	Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function. <i>American Journal of Cardiology</i> , 1996, 77, 498-502.	1.6	62
18	Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1086-1092.	2.9	62

#	ARTICLE	IF	CITATIONS
19	Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. <i>European Heart Journal</i> , 2011, 32, 316-325.	2.2	60
20	Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis. <i>Circulation</i> , 1996, 93, 1913-1918.	1.6	59
21	Tissue Factor Is Induced by Resistin in Human Coronary Artery Endothelial Cells by the NF- κ B-Dependent Pathway. <i>Journal of Vascular Research</i> , 2011, 48, 59-66.	1.4	58
22	The effect of dual-chamber closed-loop stimulation on syncope recurrence in healthy patients with tilt-induced vasovagal cardioinhibitory syncope: a prospective, randomised, single-blind, crossover study. <i>Heart</i> , 2013, 99, 1609-1613.	2.9	52
23	Differential enhancement of postischemic segmental systolic thickening by diltiazem. <i>Journal of the American College of Cardiology</i> , 1990, 15, 737-747.	2.8	51
24	Dispersion of repolarization and beta-thalassemia major: the prognostic role of QT and JT dispersion for identifying the high-risk patients for sudden death. <i>European Journal of Haematology</i> , 2011, 86, 324-331.	2.2	51
25	Left atrial appendage closure using AMPLATZER [®] devices: A large, multicenter, Italian registry. <i>International Journal of Cardiology</i> , 2017, 248, 103-107.	1.7	51
26	Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 278, H1507-H1516.	3.2	49
27	The inhibitors of the tissue factor:factor VII pathway. <i>Thrombosis Research</i> , 2002, 106, V257-V265.	1.7	49
28	The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. <i>American Heart Journal</i> , 1993, 125, 11-23.	2.7	48
29	Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion. <i>American Heart Journal</i> , 1988, 115, 499-504.	2.7	46
30	Endogenous Tissue Factor Pathway Inhibitor Modulates Thrombus Formation in an In Vivo Model of Rabbit Carotid Artery Stenosis and Endothelial Injury. <i>Circulation</i> , 2000, 102, 113-117.	1.6	46
31	C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture. <i>International Journal of Cardiology</i> , 2013, 168, 981-986.	1.7	46
32	Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury. <i>Journal of the American College of Cardiology</i> , 1991, 17, 101-110.	2.8	44
33	The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 517-523.	1.5	44
34	Experimental Carotid Stenosis and Endothelial Injury in the Rabbit: An In Vivo Model to Study Intravascular Platelet Aggregation. <i>Thrombosis and Haemostasis</i> , 1992, 67, 302-305.	3.4	44
35	Adipose tissue and vascular inflammation in coronary artery disease. <i>World Journal of Cardiology</i> , 2014, 6, 539.	1.5	42
36	Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: Further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo. <i>Journal of the American College of Cardiology</i> , 1990, 15, 718-726.	2.8	41

#	ARTICLE	IF	CITATIONS
37	Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 108, 2864-2869.	1.6	41
38	Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 138-145.	1.9	41
39	Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. <i>Journal of the American College of Cardiology</i> , 1990, 16, 705-713.	2.8	40
40	Activating stimuli induce platelet microRNA modulation and proteome reorganisation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 96-108.	3.4	40
41	Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. <i>Clinical Therapeutics</i> , 2019, 41, 2549-2557.	2.5	40
42	Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis. <i>Circulation</i> , 1995, 92, 1005-1010.	1.6	40
43	Role of new antiplatelet agents as adjunctive therapies in thrombolysis. <i>American Journal of Cardiology</i> , 1991, 67, 12-18.	1.6	39
44	C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2011, 152, 7-12.	1.7	39
45	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 370-376.	2.7	39
46	Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. <i>Vascular Pharmacology</i> , 2018, 111, 62-70.	2.1	38
47	Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. <i>Journal of the American College of Cardiology</i> , 2001, 38, 569-576.	2.8	37
48	Free radicals and antioxidants in cardiovascular diseases. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 159-171.	1.5	37
49	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 1944.	2.4	36
50	Increased dispersion of ventricular repolarization in emery dreifuss muscular dystrophy patients. <i>Medical Science Monitor</i> , 2012, 18, CR643-CR647.	1.1	34
51	The role of adiposity as a determinant of an inflammatory milieu. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 450-460.	1.5	33
52	Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 207-214.	1.9	33
53	Myocardial Strain Analysis in a Doxorubicin-Induced Cardiomyopathy Model. <i>Ultrasound in Medicine and Biology</i> , 2008, 34, 370-378.	1.5	32
54	Does Bachmann's bundle pacing prevent atrial fibrillation in myotonic dystrophy type 1 patients? A 12 months follow-up study. <i>Europace</i> , 2010, 12, 1219-1223.	1.7	32

#	ARTICLE	IF	CITATIONS
55	Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients. International Journal of Hematology, 2011, 93, 446-451.	1.6	31
56	Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque. Current Cardiology Reviews, 2017, 13, 110-117.	1.5	31
57	Atrial Fibrillation and Malignancy: The Clinical Performance of Non-Vitamin K Oral Anticoagulants—A Systematic Review. Seminars in Thrombosis and Hemostasis, 2019, 45, 205-214.	2.7	30
58	Increased Heterogeneity of Ventricular Repolarization in Obese Nonhypertensive Children. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 1533-1539.	1.2	29
59	Upregulation of TH/IL-17 Pathway-Related Genes in Human Coronary Endothelial Cells Stimulated with Serum of Patients with Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine, 2017, 4, 1.	2.4	28
60	The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator. Journal of Clinical Medicine, 2020, 9, 1111.	2.4	26
61	The effect of atrial preference pacing on paroxysmal atrial fibrillation incidence in myotonic dystrophy type 1 patients: a prospective, randomized, single-blind cross-over study. Europace, 2012, 14, 486-489.	1.7	25
62	Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: Studies in a rabbit model of coronary artery occlusion-reperfusion. Journal of the American College of Cardiology, 1993, 21, 493-501.	2.8	24
63	Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine. Biochemical Pharmacology, 1999, 58, 1341-1348.	4.4	24
64	Expression of functional tissue factor in activated T-lymphocytes in vitro and in vivo : A possible contribution of immunity to thrombosis?. International Journal of Cardiology, 2016, 218, 188-195.	1.7	24
65	Activated platelets stimulate tissue factor expression in smooth muscle cells. Thrombosis Research, 2003, 112, 51-57.	1.7	23
66	Role of Tissue Factor Pathway Inhibitor in the Regulation of Tissue Factor-Dependent Blood Coagulation. Cardiovascular Drug Reviews, 2002, 20, 67-80.	4.1	22
67	Role of Tissue Factor in the Coagulation Network. Seminars in Thrombosis and Hemostasis, 2015, 41, 708-717.	2.7	22
68	Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. Journal of Thrombosis and Thrombolysis, 2018, 45, 206-212.	2.1	22
69	Reference ranges and physiologic variations of left E/e' ratio in healthy adults: Clinical and echocardiographic correlates. Journal of Cardiovascular Echography, 2018, 28, 101.	0.4	22
70	Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?. Internal and Emergency Medicine, 2011, 6, 29-34.	2.0	21
71	Cognitive Function and Atrial Fibrillation: From the Strength of Relationship to the Dark Side of Prevention. Is There a Contribution from Sinus Rhythm Restoration and Maintenance?. Medicina (Lithuania), 2019, 55, 587.	2.0	21
72	Does a high percentage of right ventricular pacing influence the incidence of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients?. Kardiologia Polska, 2013, 71, 1147-1153.	0.6	21

#	ARTICLE	IF	CITATIONS
73	The Main Determinant of Hypotension in Nitroglycerine Tilt-Induced Vasovagal Syncope. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 739-748.	1.2	20
74	Reactive oxygen species induce a procoagulant state in endothelial cells by inhibiting tissue factor pathway inhibitor. Journal of Thrombosis and Thrombolysis, 2015, 40, 186-192.	2.1	19
75	Nursing Teleconsultation for the Outpatient Management of Patients with Cardiovascular Disease during COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2021, 18, 2087.	2.6	19
76	The adipokine apelin-13 induces expression of prothrombotic tissue factor. Thrombosis and Haemostasis, 2015, 113, 363-372.	3.4	18
77	Fluid challenge predicts clinical worsening in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 261, 167-171.	1.7	18
78	Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion. American Journal of Cardiology, 2020, 134, 83-90.	1.6	18
79	Ceruloplasmin impairs endothelium-dependent relaxation of rabbit aorta. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H2843-H2849.	3.2	17
80	Does cardiac pacing reduce syncopal recurrences in cardioinhibitory vasovagal syncope patients selected with head-up tilt test? Analysis of a 5-year follow-up database. International Journal of Cardiology, 2018, 270, 149-153.	1.7	17
81	Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study. American Journal of Cardiovascular Drugs, 2019, 19, 421-427.	2.2	17
82	Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF- κ B pathway.. European Journal of Pharmacology, 2020, 885, 173422.	3.5	17
83	Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports. Journal of Cardiovascular Pharmacology, 2021, 78, e20-e29.	1.9	17
84	Oxidized low-density lipoproteins induce tissue factor expression in T-lymphocytes via activation of lectin-like oxidized low-density lipoprotein receptor-1. Cardiovascular Research, 2020, 116, 1125-1135.	3.8	15
85	Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction. American Journal of Cardiology, 1990, 66, 1281-1286.	1.6	14
86	Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries. American Journal of Cardiology, 1991, 68, 1274-1278.	1.6	14
87	The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations. Expert Review of Cardiovascular Therapy, 2012, 10, 1533-1543.	1.5	14
88	Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?. Journal of Cardiovascular Development and Disease, 2022, 9, 27.	1.6	14
89	Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion. American Heart Journal, 1990, 120, 801-807.	2.7	13
90	Local cytokine production in patients with Acute Coronary Syndromes: A look into the eye of the perfect (cytokine) storm. International Journal of Cardiology, 2014, 176, 227-229.	1.7	13

#	ARTICLE	IF	CITATIONS
91	Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure. Journal of Affective Disorders, 2020, 272, 132-137.	4.1	13
92	Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study. Journal of Clinical Medicine, 2020, 9, 1621.	2.4	13
93	Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes. American Journal of Cardiology, 1990, 66, G48-G53.	1.6	12
94	Safety and feasibility of balloon aortic valvuloplasty in non-TAVI centers: The "BAV for life" experience. Catheterization and Cardiovascular Interventions, 2019, 93, E63-E70.	1.7	12
95	The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 3926.	2.4	12
96	Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. Heart Failure Clinics, 2022, 18, 73-87.	2.1	12
97	A Simple Method for the Isolation, Cultivation, and Characterization of Endothelial Cells from Rabbit Coronary Circulation. Thrombosis Research, 1999, 96, 329-333.	1.7	11
98	Transcoronary Th-17 lymphocytes and acute coronary syndromes: new evidence from the crime scene?. International Journal of Cardiology, 2011, 153, 215-216.	1.7	11
99	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-6.	1.7	11
100	Patent foramen ovale with complex anatomy: Comparison of two different devices (Amplatzer Septal) Tj ETQq0 0 0 rgBT /Overlock 10 T 279, 47-50.	1.7	11
101	Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2020, 46, 970-976.	2.7	11
102	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases (Basel, Switzerland), 2018, 6, 22.	2.5	10
103	Update on Direct oral anticoagulants in atrial fibrillation patients undergoing cardiac interventional procedures. Journal of Cardiovascular Pharmacology, 2019, 75, 1.	1.9	10
104	Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. Vascular Pharmacology, 2021, 137, 106822.	2.1	10
105	The Impact of the COVID-19 Outbreak on Patients'™ Adherence to PCSK9 Inhibitors Therapy. Journal of Clinical Medicine, 2022, 11, 475.	2.4	9
106	Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation. European Journal of Clinical Pharmacology, 2022, 78, 879-886.	1.9	9
107	Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1684-1689.	2.4	8
108	Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome. Journal of Interventional Cardiology, 2017, 30, 5-15.	1.2	8

#	ARTICLE	IF	CITATIONS
109	Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review. <i>Neuromuscular Disorders</i> , 2021, 31, 281-290.	0.6	8
110	The Role of New Imaging Technologies in the Diagnosis of Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2022, 18, 61-72.	2.1	8
111	The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?. <i>European Respiratory Journal</i> , 2022, 60, 2102276.	6.7	8
112	Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding. <i>Medicina (Lithuania)</i> , 2021, 57, 444.	2.0	7
113	Mitral prolapse: An old mysterious entity “ The incremental role of multimodality imaging in sports eligibility. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 207.	0.4	7
114	Cardioinhibitory syncope with asystole during nitroglycerin potentiated head up tilt test: prevalence and clinical predictors. <i>Clinical Autonomic Research</i> , 2022, 32, 167-173.	2.5	7
115	Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study. <i>BioMed Research International</i> , 2019, 2019, 1-6.	1.9	6
116	Transcatheter Aortic Valve Implantation: The New Challenges of Cardiac Rehabilitation. <i>Journal of Clinical Medicine</i> , 2021, 10, 810.	2.4	6
117	Left Ventricular Deformation and Vortex Analysis in Heart Failure: From Ultrasound Technique to Current Clinical Application. <i>Diagnostics</i> , 2021, 11, 892.	2.6	6
118	Targeting Tissue Factor as an Antithrombotic Strategy. <i>Seminars in Vascular Medicine</i> , 2003, 03, 205-214.	2.1	5
119	Transcatheter closure of atrial septal defect in the elderly: Early outcomes and mid-term follow-up. <i>International Journal of Cardiology Congenital Heart Disease</i> , 2020, 1, 100058.	0.4	5
120	Inhibition of the Tissue Factor Coagulation Pathway. <i>Current Vascular Pharmacology</i> , 2004, 2, 319-327.	1.7	5
121	Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 739-749.	2.1	5
122	Heart transplantation in a patient with Myotonic Dystrophy type 1 and end-stage dilated cardiomyopathy: a short term follow-up. <i>Acta Myologica</i> , 2018, 37, 267-271.	1.5	5
123	Nutcracker syndrome. <i>European Journal of Echocardiography</i> , 2009, 10, 993-993.	2.3	4
124	When chewing gum is more than just a bad habit. <i>Lancet, The</i> , 2009, 373, 1918.	13.7	4
125	Characteristics of new P2Y12 inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S22-S30.	1.5	4
126	Radial pseudoaneurysm in elderly: a rare event with undefined therapeutical approach. A case report and literature review. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.6	4

#	ARTICLE	IF	CITATIONS
127	High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need. Translational Medicine @ UniSa, 2015, 12, 29-40.	0.5	4
128	SERUM cardiac-specific biomarkers and atrial fibrillation in myotonic dystrophy type I. Journal of Cardiovascular Electrophysiology, 2019, 30, 2914-2919.	1.7	3
129	Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation. Acta Myologica, 2017, 36, 218-222.	1.5	3
130	Fluid challenge and balloon occlusion testing in patients with atrial septal defects. Heart, 2021, , heartjnl-2021-319676.	2.9	2
131	ST-elevation during head up tilt test: a challenging case in syncope unit. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	2
132	Evolving Concepts in LDL-Lowering Strategies: Are We There?. Journal of Clinical & Experimental Cardiology, 2016, 7, .	0.0	2
133	Single-Chamber Leadless Cardiac Pacemaker in Patients Without Atrial Fibrillation: Findings From Campania Leadless Registry. Frontiers in Cardiovascular Medicine, 2021, 8, 781335.	2.4	2
134	Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis.. Journal of Cardiovascular Echography, 2021, 31, 157-164.	0.4	2
135	How to study the effects of platelet aggregation and thrombosis on coronary vasomotion and their clinical relevance. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2002, 3, 220-5.	0.1	2
136	Novel antithrombotic strategies in cardiovascular diseases. Current Opinion in Investigational Drugs, 2005, 6, 298-306.	2.3	2
137	Serotonergic Mechanisms in the Regulation of the Human Coronary Circulation in Vivo. Endothelium: Journal of Endothelial Cell Research, 1993, 1, 131-136.	1.7	1
138	Massive chronic atrial thrombosis. International Journal of Cardiology, 2003, 90, 323-324.	1.7	1
139	Inflammation: The Link Between Obesity and Cardiovascular Risk. Current Cardiovascular Risk Reports, 2010, 4, 101-111.	2.0	1
140	Rapid ultrasound score as an indicator of atherosclerosisâ€™ clinical manifestations in a population of hypertensives. Anatolian Journal of Cardiology, 2013, 14, 9-15.	0.4	1
141	Preoperative evaluation before MitraClip [®] : present and future perspective. Future Cardiology, 2014, 10, 725-744.	1.2	1
142	Peripheral Artery Disease and Abdominal Aortic Aneurysm: The Forgotten Diseases in COVID-19 Pandemic. Results from an Observational Study on Real-World Management. Medicina (Lithuania), 2021, 57, 672.	2.0	1
143	Edoxaban (LIXIANA [®]) in the treatment of venous thromboembolism. Future Cardiology, 2021, 17, 779-791.	1.2	1
144	First Multi-Detector Computed Tomography Evidence of Transcatheter Pacing System Migration and Embolization into the Pulmonary Vasculature. Korean Journal of Thoracic and Cardiovascular Surgery, 2020, 53, 310-312.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Mickey Mouse in the cath lab. International Journal of Cardiology, 2015, 201, 378-379.	1.7	0
146	Animal models of platelet-dependent thrombosis. , 2002, , 499-512.		0
147	Specific Platelet Mediators and the Abrupt Progression of Coronary Artery Stenoses. , 1992, , 283-294.		0
148	Cyclic flow alterations and neointimal proliferation following experimental coronary stenosis and endothelial injury. Developments in Cardiovascular Medicine, 1993, , 385-393.	0.1	0
149	A systolic murmur late after infective endocarditis: Looking for the guilty. Journal of Cardiovascular Echography, 2019, 29, 183.	0.4	0
150	Usefulness of the external loop recorder in a patient with Myotonic Dystrophy type 1 and recurrent episodes of palpitations: evaluation of the follow-up from diagnosis to 6 month-post-cardiac interventional treatment. Acta Myologica, 2018, 37, 5-8.	1.5	0
151	Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy. Acta Myologica, 2018, 37, 227-231.	1.5	0
152	First Multi-Detector Computed Tomography Evidence of Transcatheter Pacing System Migration and Embolization into the Pulmonary Vasculature. Korean Journal of Thoracic and Cardiovascular Surgery, 2020, , .	0.6	0
153	799â€fBiventricular dysfunction and lung congestion in athletes on anabolic androgenic steroids: a speckle tracking and stress lung echocardiography analysis. European Heart Journal Supplements, 2021, 23, .	0.1	0
154	589â€fExternal validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.1	0